{"id": "synth-001", "agent": "agent-stage2-synthesize", "input": {"studies": [{"pmid": "12345678", "findings": "Caffeine 200mg improved reaction time by 15%", "quality": "high", "n": 120}, {"pmid": "12345679", "findings": "Caffeine 150mg improved attention by 12%", "quality": "moderate", "n": 80}, {"pmid": "12345680", "findings": "No effect of caffeine 100mg on memory", "quality": "high", "n": 150}], "question": "Does caffeine improve cognitive performance?"}, "expected_output": {"conclusion": "Moderate-to-high quality evidence suggests caffeine (150-200mg) improves cognitive performance, particularly reaction time and attention, with no consistent effect on memory.", "evidence_strength": "moderate", "consistency": "consistent for reaction time and attention; inconsistent for memory", "heterogeneity": "low for reaction time outcomes", "limitations": ["dose-response relationship unclear", "short-term studies only"]}, "tags": ["synthesis", "cognitive", "pharmacology"]}
{"id": "synth-002", "agent": "agent-stage2-synthesize", "input": {"studies": [{"pmid": "23456789", "findings": "Metformin reduced MACE by 22% (observational)", "quality": "moderate", "n": 5000}, {"pmid": "23456790", "findings": "No CV benefit of metformin in RCT", "quality": "high", "n": 1200}, {"pmid": "23456791", "findings": "Metformin associated with 15% lower CV events (registry)", "quality": "low", "n": 20000}], "question": "Does metformin reduce cardiovascular events in type 2 diabetes?"}, "expected_output": {"conclusion": "Evidence is mixed and limited by study design heterogeneity. Observational data suggest potential cardiovascular benefit, but the sole RCT found no effect. Registry data show modest associations but are subject to confounding.", "evidence_strength": "low to moderate", "consistency": "inconsistent between RCTs and observational studies", "heterogeneity": "high due to study design variation", "limitations": ["limited high-quality RCT evidence", "confounding in observational studies", "heterogeneous populations"]}, "tags": ["synthesis", "cardiology", "diabetes", "conflicting-evidence"]}
{"id": "synth-003", "agent": "agent-stage2-synthesize", "input": {"studies": [{"pmid": "34567890", "findings": "Mindfulness reduced anxiety (SMD=-0.56)", "quality": "high", "n": 2500, "study_type": "meta-analysis"}, {"pmid": "34567891", "findings": "Mindfulness superior to CBT for anxiety (d=0.24)", "quality": "moderate", "n": 800}, {"pmid": "34567892", "findings": "Mindfulness reduced anxiety relapse by 30%", "quality": "moderate", "n": 400}], "question": "Is mindfulness effective for anxiety disorders?"}, "expected_output": {"conclusion": "Strong evidence supports mindfulness-based interventions for reducing anxiety symptoms, with effect sizes in the moderate range. Emerging evidence suggests mindfulness may reduce relapse risk and be comparable to CBT.", "evidence_strength": "high", "consistency": "highly consistent across studies", "heterogeneity": "moderate (IÂ²=64% in primary meta-analysis)", "limitations": ["waitlist controls predominate", "long-term outcomes understudied", "optimal dose unclear"]}, "tags": ["synthesis", "psychiatry", "behavioral", "strong-evidence"]}
{"id": "synth-004", "agent": "agent-stage2-synthesize", "input": {"studies": [{"pmid": "45678901", "findings": "Vitamin D did not reduce falls (RR=0.95, p=0.56)", "quality": "high", "n": 800}, {"pmid": "45678902", "findings": "Vitamin D reduced falls by 14% in deficient elderly", "quality": "moderate", "n": 600}, {"pmid": "45678903", "findings": "No effect of vitamin D on fractures (HR=1.02)", "quality": "high", "n": 2000}], "question": "Does vitamin D supplementation prevent falls in elderly?"}, "expected_output": {"conclusion": "Overall evidence does not support routine vitamin D supplementation for fall prevention in unselected elderly populations. Benefit may be limited to those with documented vitamin D deficiency.", "evidence_strength": "moderate to high", "consistency": "inconsistent; possible effect modification by baseline vitamin D status", "heterogeneity": "moderate", "limitations": ["heterogeneous baseline vitamin D levels", "varying supplementation doses", "limited subgroup analyses"]}, "tags": ["synthesis", "geriatrics", "null-result", "subgroup-effects"]}
{"id": "synth-005", "agent": "agent-stage2-synthesize", "input": {"studies": [{"pmid": "67890123", "findings": "Empagliflozin reduced HF events (HR=0.79) in HFpEF", "quality": "high", "n": 5988}, {"pmid": "67890124", "findings": "Dapagliflozin reduced HF events (HR=0.74) in HFrEF", "quality": "high", "n": 4744}, {"pmid": "67890125", "findings": "SGLT2i class benefit on CV death (HR=0.82) across HF spectrum", "quality": "high", "n": 15000, "study_type": "meta-analysis"}], "question": "Are SGLT2 inhibitors effective for heart failure?"}, "expected_output": {"conclusion": "High-quality evidence demonstrates a consistent class effect of SGLT2 inhibitors in reducing heart failure events and cardiovascular death across the spectrum of left ventricular ejection fraction.", "evidence_strength": "high", "consistency": "highly consistent across trials and HF phenotypes", "heterogeneity": "low", "limitations": ["limited data in acute HF", "mechanism not fully elucidated", "cost-effectiveness varies by region"]}, "tags": ["synthesis", "cardiology", "class-effect", "landmark-trials"]}
